Get the Stockscreener App
200.69
2.01%
-4.11
After Hours:
201.00
0.31
+0.15%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $200.69, with a volume of 1.08M.
It is down -2.01% in the last 24 hours and up +9.31% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$204.80
Open:
$202.81
24h Volume:
1.08M
Relative Volume:
0.29
Market Cap:
$311.24B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
61.21
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
-0.77%
1M Performance:
+9.31%
6M Performance:
+139.29%
1Y Performance:
+196.92%
1-Day Range:
$200.67
$203.37
1-Week Range:
$199.50
$205.30
52-Week Range:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Lobbying Update: $2,280,000 of ASTRAZENECA PHARMACEUTICALS LP lobbying was just disclosed - Quiver Quantitative
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to drive sustained ups - AD HOC NEWS
AstraZeneca stock slips as weak momentum limits further upside - Traders Union
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab - GuruFocus
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare‑ups - Reuters
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial - Citeline News & Insights
Generic Injectables Market Major PlayersAstrazeneca, Baxter - openPR.com
AstraZeneca (AZN) Stock: Tozorakimab Achieves Phase III COPD Success in MIRANDA Study - Blockonomi
AstraZeneca (AZN) Stock: COPD Drug Tozorakimab Hits Phase III Trial Goals - CoinCentral
AstraZeneca (AZN) scores third positive Phase III COPD result for tozorakimab - Stock Titan
COPD patients saw fewer flare-ups in AstraZeneca's third Phase III trial - Stock Titan
Astrazeneca Says Tozorakimab Significantly Lowers COPD in Phase 3 Study - marketscreener.com
AstraZeneca's Tozorakimab meets primary endpoint in "pivotal" trial - marketscreener.com
AstraZeneca reports positive top-line data from Phase III MIRANDA trial - Sharecast.com
Astrazeneca says tozorakimab meets primary endpoint in phase III Miranda trial for COPD - marketscreener.com
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare-ups - marketscreener.com
AstraZeneca Reports Positive Late-stage Data for Chronic Obstructive Pulmonary Disease Drug Tozorakimab - marketscreener.com
AstraZeneca PLC stock (US6549022043): Is its oncology pipeline strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare-ups - marketscreener.com
AstraZeneca : Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - marketscreener.com
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained upside? - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained U.S. in - AD HOC NEWS
AstraZeneca’s Danicopan Korea Study: Real-World Data That Could Shape AZN’s Rare Disease Edge - TipRanks
AstraZeneca PLCdepositary receipt (AZN) price target increased by 107.33% to 202.76 - MSN
Mirae Asset Global Investments Co. Ltd. Acquires 42,665 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
AZN Stock Quote Price and Forecast - CNN
AST Large-Cap Value Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca stock holds steady after Assetmark Inc. and Pursuit Wealth buy shares - Traders Union
Astrazeneca Plc $AZN Shares Sold by Iams Wealth Management LLC - MarketBeat
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by Pr - GuruFocus
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
AstraZeneca (AZN) Advances Portfolio with Strategic Update - GuruFocus
AstraZeneca (AZN) Faces Rising Drug Prices Amid Senate Scrutiny - GuruFocus
Pursuit Wealth Management LLC Takes Position in Astrazeneca Plc $AZN - MarketBeat
Assetmark Inc. Buys 25,004 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Australia
AstraZeneca stock holds steady after $191 million grant for Albemarle facility approved - Traders Union
ZWJ Investment Counsel Inc. Lowers Holdings in Astrazeneca Plc $AZN - MarketBeat
Bingham Private Wealth LLC Takes $669,000 Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca plc stock (GB0009895292): Why does its oncology dominance matter more now for U.S. inves - AD HOC NEWS
AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study - TipRanks
AstraZeneca plc stock (GB0009895292): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
32,091 Shares in Astrazeneca Plc $AZN Bought by Third View Private Wealth LLC - MarketBeat
AstraZeneca Adds to Demands on Hospitals Seeking Drug Discounts - Bloomberg Law News
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
Yousif Capital Management LLC Decreases Stake in Astrazeneca Plc $AZN - MarketBeat
Hardman Johnston Global Advisors LLC Reduces Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca India to divest Bengaluru manufacturing site for INR 3,400 crore - Prop News Time
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):